Inactive Instrument

Opko Health Inc. Stock Nyse

Equities

US68375N1037

Healthcare Facilities & Services

End-of-day quote Nyse
- USD - Intraday chart for Opko Health Inc.
Sales 2024 * 715M 979M Sales 2025 * 754M 1.03B Capitalization 899M 1.23B
Net income 2024 * -265M -363M Net income 2025 * -195M -267M EV / Sales 2024 * 1.26 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.19 x
P/E ratio 2024 *
-3.46 x
P/E ratio 2025 *
-4.78 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 45.64%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 87 07-03-26
Director of Finance/CFO 46 07-02-28
President 72 22-05-08
Members of the board TitleAgeSince
Chief Executive Officer 87 07-03-26
Director/Board Member 77 20-12-17
Director/Board Member 68 07-12-31
More insiders
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
More about the company